drugset
drugset / Trial / NCT05045313

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

NCT05045313 ↗

Phase 1 Completed 28 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of DBPR108 with Warfarin sodium, Digoxin, or Probenecid in healthy subjects. This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of Warfarin sodium, Digoxin, or Probenecid.

Timeline

Start
2021-10-20
Primary completion
2021-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DBPR108 Small molecule 100 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Probenecid Small molecule 500 mg Oral
Subject Warfarin Small molecule 5 mg Oral

Indications

No indication recorded.